[Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].

Abstract

BACKGROUND:

Continuous subcutaneous infusion of apomorphine (CAI) has shown efficacy in the treatment of motor fluctuations but its place in the therapeutic arsenal remains poorly defined in terms of indication, acceptability and long-term tolerance. Indeed, few studies have been carried out with a follow-up greater than 12 months. The main objective was to assess the quality of life of Parkinson's disease (PD) patients treated with CAI. We also evaluate the effectiveness on the motor fluctuations, the long-term tolerance of this treatment with its causes of discontinuation and the treatment regimens used.

METHODS:

We conducted a retrospective study of 81 PD patients treated with CAI between April 2003 and June 2012. Data were collected from medical records. A repeated measures analysis of variance by the linear mixed model was used (significance level: 5%).

RESULTS:

In August 2012, 27/81 patients were still treated with CAI with a mean duration of 28 months, 46/81 discontinued CAI (9 precociously), and 8 were lost to view. We didn't show improvement in the quality of life nor efficacy of CAI on the UPDRS IV score (P=0.54) and dyskinesia score (P=0.95). The CGI score patient also reflects this result with a majority response suggesting no significant change with CAI. We observed relative good cognitive and psychiatric tolerance. Adverse events were frequent but often benign. The average (±SD) rate of apomorphine was 3.15±1.71 mg/h and the oral dopaminergic treatment was decreased by 37.8%.

DISCUSSION:

The results are consistent with the literature except for the lack of efficiency on motor fluctuations which may be due to the use of too small doses of apomorphine. This seems to be a leading cause of discontinuation of CAI, especially when it is associated with side effects or important constraints. For better efficiency on motor fluctuations, we recommend the use of apomorphine at higher doses to obtain an optimal continuous dopaminergic stimulation.

• Authors: M Rambour, C Moreau, J Salleron, D Devos, A Kreisler, E Mutez, C Simonin, A Annic, K Dujardin, A Destée, L Defebvre
• Journal: Revue neurologique (Rev Neurol (Paris)) Vol. 170 Issue 3 Pg. 205-15 (Mar 2014) ISSN: 0035-3787 [Print] France
• Vernacular Title: Le traitement par apomorphine en perfusion continue sous-cutanée dans la maladie de Parkinson : analyse rétrospective d'une série de 81 patients.
• PMID: 24594365 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2014. Published by Elsevier Masson SAS.

Chemical References

• Antiparkinson Agents
• Dopamine Agonists
• Apomorphine

Topics

• Adult
• Aged
• Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
• Apomorphine (administration & dosage, adverse effects, therapeutic use)
• Dopamine Agonists (administration & dosage, adverse effects, therapeutic use)
• Drug Eruptions (etiology)
• Drug Evaluation
• Female
• Hallucinations (chemically induced)
• Humans
• Infusions, Subcutaneous
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Patient Acceptance of Health Care
• Quality of Life
• Retrospective Studies
• Severity of Illness Index
• Treatment Outcome